Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Yet another susceptibility variant for ALL: what's next?

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  5. A small change makes a big difference in Hodgkin lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Long-lasting Tumour on the Upper Lip of a 28-year-old Woman: A Quiz

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Patient-reported Outcomes During Treatment in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Cutaneous T-cell lymphomas (CTCLs) are the most frequent primary skin lymphomas. Nevertheless, diagnosis of early disease has proven difficult because of a clinical and histologic resemblance to benign inflammatory skin diseases. To address whether microRNA (miRNA) profiling can discriminate CTCL from benign inflammation, we studied miRNA expression levels in 198 patients with CTCL, peripheral T-cell lymphoma (PTL), and benign skin diseases (psoriasis and dermatitis). Using microarrays, we show that the most induced (miR-326, miR-663b, and miR-711) and repressed (miR-203 and miR-205) miRNAs distinguish CTCL from benign skin diseases with > 90% accuracy in a training set of 90 samples and a test set of 58 blinded samples. These miRNAs also distinguish malignant and benign lesions in an independent set of 50 patients with PTL and skin inflammation and in experimental human xenograft mouse models of psoriasis and CTCL. Quantitative (q)RT-PCR analysis of 103 patients with CTCL and benign skin disorders validates differential expression of 4 of the 5 miRNAs and confirms previous reports on miR-155 in CTCL. A qRT-PCR-based classifier consisting of miR-155, miR-203, and miR-205 distinguishes CTCL from benign disorders with high specificity and sensitivity, and with a classification accuracy of 95%, indicating that miRNAs have a high diagnostic potential in CTCL.
OriginalsprogEngelsk
TidsskriftBlood
Vol/bind118
Udgave nummer22
Sider (fra-til)5891-900
Antal sider10
ISSN0006-4971
DOI
StatusUdgivet - 2011

ID: 33218784